Anti-MMP9 ADCC Enhanced Antibody (GS-5745) is an ADCC enhanced antibody produced by our Afuco™ platform. GS-5745 is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. Inhibiting MMP9 is expected to block paracrine signaling and metastasis and to alter the immune environment within the tumor. Preliminary safety data demonstrate a manageable safety profile for GS-5745 alone and in combination with chemotherapy. The study has been expanded to enroll additional subjects with pancreatic and esophagogastric cancer to identify potential pharmacodynamic and predictive biomarkers of response.
Figure 1 Efficacy endpoints.
The proportion of patients achieving [A] EBS clinical remission, [B] MCS response, [C] endoscopic response, and [D] mucosal healing at Week 8. [E] Change from baseline in partial MCS over time. [A–D] Values indicate percentage of patients per treatment group achieving response. Error bars indicate upper and lower 95% confidence interval. [E] Data represented as mean with error bars indicating SD. EBS clinical remission defined as endoscopic subscore of 0 or 1, rectal bleeding score of 0, and ≥1-point decrease in stool frequency to achieve a subscore of 0 or 1; MCS response defined as reduction of ≥3 points and at least 30% from baseline with decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1; endoscopic response defined as endoscopic subscore of 0 or 1; mucosal healing defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. Partial MCS comprised subscores from rectal bleeding, stool frequency, and PGA. aPatients with mucosal healing at baseline were excluded from the analysis. EBS, endoscopy/bleeding/stool; MCS, Mayo clinical score; PGA, physician's global assessment; Q2W, every 2 weeks; QW, weekly; SD, standard deviation.
Sandborn, W. J., Bhandari, B. R., Randall, C., Younes, Z. H., Romanczyk, T., Xin, Y., ... & Sundy, J. S. (2018). Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. Journal of Crohn's and Colitis,12(9), 1021-1029.
Figure 2 Mean plasma concentration vs time curves for andecaliximab Q2W and QW.
Error bars indicate SD. Arrows indicate drug administration for Q2W dosing. All PK samples were collected before dosing on respective treatment days. For the 150 mg Q2W group, the Week 8 concentration was determined 2 weeks following the previous dose, whereas Week 1 and Week 5 concentrations were determined 1 week following the previous dose. PK, pharmacokinetic; Q2W, every 2 weeks; QW, weekly; SD, standard deviation.
Sandborn, W. J., Bhandari, B. R., Randall, C., Younes, Z. H., Romanczyk, T., Xin, Y., ... & Sundy, J. S. (2018). Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. Journal of Crohn's and Colitis,12(9), 1021-1029.
Figure 3 GS-5745 demonstrate noncompetitive inhibition of MMP9: Antibody-mediated inhibition of MMP9 activity was assessed at multiple concentrations of substrate (a fluorogenic peptide).
Marshall, D. C., Lyman, S. K., McCauley, S., Kovalenko, M., Spangler, R., Liu, C., ... & Mikels-Vigdal, A. (2015). Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PloS one,10(5), e0127063.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-533CL | Anti-Human MMP9 Recombinant Antibody (GS-5745) | WB, Inhib | Antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0824CL | Human Anti-MMP9 Recombinant Antibody (TAB-0824CL) | ELISA | Human IgG4 |
TAB-0825CL | Human Anti-MMP9 Recombinant Antibody (TAB-0825CL) | ELISA | Human IgG4 |
TAB-0824CL-S(P) | Human Anti-MMP9 Recombinant Antibody; scFv Fragment (TAB-0824CL-S(P)) | ELISA | Human scFv |
TAB-0824CL-F(E) | Human Anti-MMP9 Recombinant Antibody; Fab Fragment (TAB-0824CL-F(E)) | ELISA | Human Fab |
TAB-0825CL-F(E) | Human Anti-MMP9 Recombinant Antibody; Fab Fragment (TAB-0825CL-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0826CL | Mouse Anti-MMP9 Recombinant Antibody (TAB-0826CL) | Inhib, ELISA, IHC | Mouse IgG |
TAB-0827CL | Mouse Anti-MMP9 Recombinant Antibody (TAB-0827CL) | ELISA | Mouse IgG |
TAB-0826CL-S(P) | Mouse Anti-MMP9 Recombinant Antibody; scFv Fragment (TAB-0826CL-S(P)) | ELISA | Mouse scFv |
TAB-0827CL-S(P) | Mouse Anti-MMP9 Recombinant Antibody; scFv Fragment (TAB-0827CL-S(P)) | ELISA | Mouse scFv |
TAB-0826CL-F(E) | Mouse Anti-MMP9 Recombinant Antibody; Fab Fragment (TAB-0826CL-F(E)) | ELISA | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBC-174 | Mouse Anti-MMP9 Recombinant Antibody (clone SDS3); Fab Fragment | ELISA, Neut | Mouse Fab |
HPAB-0027-YC-F(E) | Mouse Anti-MMP9 Recombinant Antibody; Fab Fragment (HPAB-0027-YC-F(E)) | FC | Mouse Fab |
HPAB-0028-YC-F(E) | Human Anti-MMP9 Recombinant Antibody (clone G03-VH-GL-V1/ G06-VL-GL1); Fab Fragment | Neut | Human Fab |
HPAB-0513LY-F(E) | Mouse Anti-MMP9 Recombinant Antibody (clone M4); Fab Fragment | FC | Mouse Fab |
HPAB-0514LY-F(E) | Mouse Anti-MMP9 Recombinant Antibody (clone M12); Fab Fragment | FC | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBC-174 | Mouse Anti-MMP9 Recombinant Antibody (clone SDS3); scFv Fragment | ELISA, Neut | Mouse scFv |
HPAB-0513LY-S(P) | Mouse Anti-MMP9 Recombinant Antibody (clone M4); scfv Fragment | FC | Mouse scfv |
HPAB-0514LY-S(P) | Mouse Anti-MMP9 Recombinant Antibody (clone M12); scfv Fragment | FC | Mouse scfv |
HPAB-M0311-YC-S(P) | Mouse Anti-MMP9 Recombinant Antibody (clone AB0046); scFv Fragment | ELISA | Mouse scFv |
HPAB-M0359-YC-S(P) | Human Anti-MMP9 Recombinant Antibody (clone AB0045); scFv Fragment | ELISA | Humanized scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1241CT | Recombinant Mouse anti-Human MMP9 Monoclonal antibody (26X3) | IHC-Fr, IHC-P | |
HPAB-M0311-YC | Mouse Anti-MMP9 Recombinant Antibody (clone AB0046) | ELISA, FuncS | Mouse IgG1, κ |
VS3-QX783 | Mouse Anti-MMP9 Recombinant Antibody (clone 331CT17.4.4) | WB | Mouse IgM |
VS3-QX784 | Mouse Anti-MMP9 Recombinant Antibody (clone 10A1) | WB, ICC, IHC, FC | Mouse IgG1 |
VS3-QX785 | Mouse Anti-MMP9 Recombinant Antibody (clone 5C3) | WB, IHC, ICC, FC, ELISA | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0717MZ | Chicken Anti-MMP9 Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1748CQ | Recombinant Mouse Anti-MMP9 Antibody (VMC204) | Inhib, IHC-Fr, IP, IHC-P, WB, IHC, ICC | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2263 | Hi-Affi™ Recombinant Rabbit Anti-MMP9 Monoclonal Antibody (DS2263AB) | FC, IHC-P, WB | IgG |
MOR-4331 | Hi-Affi™ Recombinant Rabbit Anti-MMP-9 Monoclonal Antibody (SI420DS) | ELISA | IgG |
MOR-4332 | Hi-Affi™ Recombinant Rabbit Anti-MMP-9 Monoclonal Antibody (SI421DS) | ELISA | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-002ML | Anti-Human MMP9 Recombinant Antibody (Andecaliximab) | ELISA, IHC, FC, IP, IF, FuncS | IgG4, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-002ML | Afuco™ Anti-MMP9 ADCC Recombinant Antibody (Andecaliximab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
There are currently no Customer reviews or questions for AFC-513CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.